Litcius/Paper detail

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

Unknown authors

2023BMJ15 citationsDOIOpen Access PDF

Topics & Concepts

MedicineDocetaxelPlaceboTrastuzumabMetastatic breast cancerOncologyDouble blindInternal medicineBreast cancerClinical trialHER2 negativeCancerAlternative medicinePathologyHER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyAdvanced Breast Cancer Therapies
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial | Litcius